Kalaris Therapeutics, Inc.

KLRS

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
SEC CIK: 0001754068

SEC filings (opens in a new tab)

Insider trades, last 90 days

None

No open-market purchases or sales were filed in the last 90 days.

View insider trades

13F holders, Q2 2026

56

−2 vs. Q1 2026
Total value $73.39M

View 13F holders

Superinvestors holding KLRS

0

None of the superinvestors held KLRS at the end of Q2 2026.

See all holders

Price chart

Chart by TradingView (opens in a new tab)

Latest insider trades

Open-market purchases and sales by KLRS insiders, newest first.

Insider trades
Filed (ET)	Trade date	Insider	Transaction	Shares	Avg price	Value	Shares after	Holding change	Filing
May 22, 20267:47 PM ET	May 20, 2026	AKKARAJU SRINIVAS and 4 othersDirector, 10% Owner	PPurchaseCommon Stock	+244.3K	$4.83	+$1.18M	2.22M	+12.3%	SEC
Mar 23, 2026	Mar 20, 2026	Hagen Brett RChief Accounting Officer	SSaleCommon Stock	−1.92K	$6.72	−$12.87K	0	−100.0%	SEC
Feb 17, 20268:15 PM ET	Dec 18, 2025	AKKARAJU SRINIVAS and 4 othersDirector, 10% Owner	PPurchaseCommon Stock	+479.85K	$10.42	+$5M	1.98M	+32.0%	SEC
Mar 27, 2025	Mar 26, 2025	Hagen Brett RChief Accounting Officer	SSaleCommon Stock	−907	$8.97	−$8.14K	1.93K	−32.0%	SEC
Feb 24, 2025	Feb 21, 2025	Sinha VikasSee Remarks	SSaleCommon Stock	−303	$10.08	−$3.05K	49.13K	−0.6%	SEC

Top 5 13F holders, Q2 2026

The largest institutional positions in KLRS at the end of Q2 2026.

Institutions holding KLRS in Q2 2026
Institution	Shares	Value	% of portfolio	Change in shares	Action
Samsara BioCapital, LLC	12,881,175	$52.43M	4.31%	−66,906−0.5%	Reduced
RTW INVESTMENTS, LP	1,300,000	$5.29M	0.05%	00.0%	Unchanged
Alyeska Investment Group, L.P.	572,687	$2.33M	0.01%	00.0%	Unchanged
Siren, L.L.C.	435,798	$1.77M	0.04%	00.0%	Unchanged
VANGUARD CAPITAL MANAGEMENT LLC	398,712	$1.62M	0.00%	+143,364+56.1%	Added